KRAS and neoplasm: We currently devise therapies for mCRC patients based on symptoms, primary tumor site, previous treatments, cancer stage, molecular evaluation (BRAF, KRAS or NRAS mutations and microsatellite instability), comorbidities, and treatment goals [5,40,41,42].